IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
In five of the six unmutated CLLs, the DLBL clones evolved from CLL tumorclones and the VH genes expressed by DLBLs were also unmutated.
|
14671632 |
2004 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The expression level of TOSO was significantly correlated with Binet staging, IGVH mutation status, age, and time to treatment in CLL.
|
21133733 |
2011 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Mutated IGHV was detected in 71·2% of Taiwanese CLL and IGHV3-23 was the most frequently used gene.
|
31230372 |
2019 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
In this study, using ChIP-sequencing, we identified EZH2 and H3K27me3 target genes in two prognostic subgroups of CLL with distinct prognosis and outcome, i.e., cases with unmutated (U-CLL, n = 6) or mutated IGHV genes (M-CLL, n = 6).
|
31216925 |
2019 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
We retrospectively analyzed 463 patients with CLL with available immunoglobulin heavy-chain variable (IGHV) gene status and B-cell receptor (BCR) configuration [heavy-chain complementary-determining region 3 (HCDR3)], of whom thirty-six developed ITP, according to previously defined criteria.
|
22322667 |
2012 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
We devised a biomarkers-only CLL prognostic system based on the two most important prognostic parameters in CLL (i.e., IGHV mutational status and fluorescence in situ hybridization [FISH] cytogenetics), separating three different risk groups: (1) low-risk (mutated IGHV + no adverse FISH cytogenetics [del(17p), del(11q)]); (2) intermediate-risk (either unmutated IGHV or adverse FISH cytogenetics) and (3) high-risk (unmutated IGHV + adverse FISH cytogenetics).
|
28120419 |
2017 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
TAp63 mRNA levels were higher in CLL with unmutated IGHV.
|
24117128 |
2013 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
We studied whether bendamustine (BENDA) alone or with rituximab (RIT) modifies <i>in vitro</i> expression of apoptosis-involved genes and proteins of chronic lymphocytic leukemia (CLL) cells depending on IGVH mutational status.
|
30187811 |
2019 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
CD49d, the alpha-chain of the integrin heterodimer α4β1, was identified among the strongest predictors of overall survival (OS) in chronic lymphocytic leukemia (CLL), along with IGHV mutational status and deletion of the 17p chromosome involving TP53.
|
27109509 |
2016 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
The mutational status of the immunoglobulin heavy chain variable (IGHV) genes identifies two subsets of CLL with different outcomes.
|
23531595 |
2013 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
We analyzed the correlation between well-established biological parameters of prognostic relevance in B-cell chronic lymphocytic leukemia (CLL) [i.e. mutational status of the immunoglobulin heavy chain variable region (IgVH), ZAP-70 and CD38 expression] and serum levels of B cell-activating factor (BAFF of the TNF family) by evaluating the impact of these variables on the time to first treatment (TFT) in a series of 169 previously untreated CLL patients in Binet stage A.
|
20546021 |
2010 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
We previously identified LDOC1 as one of the most significantly differentially expressed genes in untreated chronic lymphocytic leukemia (CLL) patients with respect to the somatic mutation status of the immunoglobulin heavy-chain variable region genes.
|
21310924 |
2011 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The pattern and location of insertions/duplications or deletions in CLL and their restriction to mutated IGHV rearranged genes strongly suggests that they resulted from somatic hypermutation.
|
16783849 |
2006 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Deletion 11q22 and IGHV status predict PFS in previously untreated CLL patients.
|
31054420 |
2019 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
To further characterize the biological features of this disease, we performed IgVH gene mutational status, FISH and high-resolution comparative genomic hybridization (HR-CGH) analysis in 17 cases of CLL/PL.
|
17410523 |
2007 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Here, we evaluated the reactivity of a panel of different CLL recombinant antibodies (rAbs) encoded by the most commonly expressed IGHV genes with a panel of selected viral and bacterial pathogens.
|
22234695 |
2012 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The two major subsets of CLL are biologically distinct, being derived from B cells at different stages of differentiation and carrying unmutated (U-CLL) or mutated (M-CLL) IGHV genes.
|
25048780 |
2014 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Highly homologous B-cell receptors, characterized by non-random combinations of immunoglobulin heavy-chain variable (IGHV) genes and heavy-chain complementarity determining region-3 (HCDR3), are expressed in a recurrent fraction of patients affected by chronic lymphocytic leukemia (CLL).
|
21897877 |
2011 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
On a cohort of 110 patients with CLL treated with first-line fludarabin, cyclophosphamide, and rituximab treatment compared with 33 untreated (watch and wait) patients with CLL, we report more frequent complex karyotypes (34 vs 15%; P = .05), unmutated IGHV (70 vs 21%; P < .0001), ATM deletion (25 vs 6%, P = .02), and NOTCH mutation (3 vs 17%, P = .04).
|
27678008 |
2017 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Taking advantage of a population of 406 untreated Chinese patients with CLL at early and advanced stage of disease, we identified the strongest prognostic markers of TTFT and, subsequently, in a cohort of 173 patients who had complete data for all 3 variables, we integrated the data of traditional staging system, cytogenetic aberrations, and mutational status of immunoglobulin heavy chain variable region (IGHV) in CLL-PI.
|
28091403 |
2017 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Therefore, a single RNA-seq assay can simultaneously yield gene expression profile, SNP and mutation information, as well as IGHV mutation status, and may one day be performed as a general test to capture multidimensional clinically relevant data in CLL.
|
25787252 |
2015 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The strongest prognostic factor in chronic B-cell lymphocytic leukemia (CLL) is the mutational status of the immunoglobulin heavy chain variable region (IGHV) genes.
|
24924909 |
2014 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia.
|
17107902 |
2006 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Searching for surrogates for IGHV mutations in chronic lymphocytic leukemia.
|
21840049 |
2011 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
These agents lead to improved outcomes in CLL, even among patients with high-risk features, such as del17p13 or TP53 mutation and unmutated immunoglobulin heavy chain (IGHV) genes.
|
30283014 |
2018 |